Our findings suggest that the impact of canagliflozin treatment on NT-proBNP concentration and its beneficial effect on volume-related parameters appear to be independent of the background use of diabetes therapy in the patient population in this study. This evidence concerns the gene NPPB and diabetes mellitus.